Shanghai Asclepius Meditec Inc. Report issue

Academic/Hospital Phase 2
Founded: Taipei Taiwan

Organization Overview

First Clinical Trial
2019
NCT03931720
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Asclepius Technology Company Group (Suzhou) Co., Ltd. | Shanghai Asclepius Meditec Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

bcma car-nk 92 cells (1 trial)

robo1 car-nk cell (2 trials)

robo1 car-nk/t cells (1 trial)

Drugs in Other Trials (1)

human fecal microbiota (Reybota) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4